← Insider Monitor
Veraxa Biotech AG - Post de-SPAC logo
VRXA

Veraxa Biotech AG - Post de-SPAC

Nasdaq · Pharmaceutical Preparations

1
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Veraxa Biotech AG develops antibody-drug conjugates and other targeted biologic therapies for cancer treatment, using its proprietary protein engineering platforms to design antibodies aimed at tumor-specific targets.

Industry
Pharmaceutical Preparations
Headquarters
Zurich
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Ziegler Christoph SamuelDirectorBuy$33KOct 20, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for VRXA.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable VRXA activity by email

Free alerts for the insider and congressional trades worth watching.

SMS is optional: we only save your number if you check the consent box and provide a valid number. US mobile numbers only.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.